rAAV Olig001 ASPA - Myrtelle
Alternative Names: AVASPA; MYR-101; rAAV-Olig001-ASPALatest Information Update: 04 Apr 2024
Price :
$50 *
At a glance
- Originator Pfizer
- Developer Myrtelle
- Class Gene therapies
- Mechanism of Action Amidohydrolase replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Canavan disease
Most Recent Events
- 02 Apr 2024 rAAV Olig001 ASPA - Myrtelle receives Regenerative Medicine Advanced Therapy (RMAT) status for Canavan disease in USA
- 31 May 2023 Myrtelle completes enrolment in its phase I/II trial for Canavan disease in USA (NCT04833907)
- 16 May 2023 Efficacy data from a phase I/II trial in Canavan disease released by Myrtelle